PHILADELPHIA (WPVI) -- Skin rashes can be a real nuisance, but they're generally benign. However, there is one time when that incessant itching can be a sign of something more serious. "This tends to ...
A single infusion of a genetically reprogrammed immune cell therapy produced confirmed cancer-free survival in more than one-third of large B-cell lymphoma patients and nearly half of follicular ...
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel ...
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...
Approximately 30%-50% of patients with relapsed or refractory B-cell non-Hodgkin lymphomas have achieved durable remissions with CAR T-cell therapies targeting CD19 over follow-up periods of up to 5 ...
Almost a third of patients with aggressive lymphoma remained cancer free 10 years after treatment with CAR T-cell therapy. The long-term data indicate that CD19-directed CAR T-cell therapy may cure ...
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The development of novel T ...
B-cell lymphoma may cause abdominal swelling, chest pressure, and bone weakening as lymphoma cells affect different organs. Treatments like chemotherapy and immunotherapy for B-cell lymphoma may ...
Uniphar will distribute denileukin diftitox across Western and Eastern Europe exclusively via managed access programs, reflecting lack of commercial approvals outside the US and Japan. Global rights ...
Lymphir, an immunotoxin, targets malignant T cells and regulatory T cells, enhancing immune response against CTCL tumors. Clinical trials showed a 36% objective response rate, with some patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results